Search for a clinical trial
Other search option(s)
19 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
ADCARE: A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer - DE - Prematurely Ended
Institution: Information not provided - DE
UNITED KINGDOM
Greater London
LONDON
BRCA Trial: Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carbopatin compared to docetaxel for patients with metastatic genetic breast cancer
Guy's Hospital
Breast Unit
UNITED KINGDOM
Greater London
LONDON
BRCA Trial: Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carbopatin compared to docetaxel for patients with metastatic genetic breast cancer
University College London - UCL Darwin Building
Research Department of Genetics, Evolution and Environment (GEE) - UCL Genetics Institute (UGI)
UNITED KINGDOM
Oxfordshire
HEADINGTON
Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours. - A Phase II Clinical Trial in Patients with BRCA defective Tumours
Churchill Hospital
Level 0, Oxford Cancer Centre - medical oncology
UNITED KINGDOM
Oxfordshire
OXFORD
Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours. - A Phase II Clinical Trial in Patients with BRCA defective Tumours
University of Oxford
Oxford University Offices
SPAIN
Cataluńa
BARCELONA
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor - ES (Completed)
Vall d'Hebron Instituto de Oncología - Centro Cellex
Vall d'Hebron Instituto de Oncología
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase II Trial of ProLindac and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer - FR
Institution: Information not provided - FR
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial - DE
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Institution: Information not provided - DE
GERMANY
Schleswig-Holstein
LÜBECK
Phase II-III: A multicenter trial of abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy - DE
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Gynäkologisches Tumorzentrum
GERMANY
Schleswig-Holstein
LÜBECK
A randomised, two-arm, multicenter phase III trial of carboplatin/paclitaxel with bevacizumab versus carboplatin/paclitaxel in patients with epithelial ovarian cancer - DE
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Gynäkologisches Tumorzentrum
ITALY
CAMPANIA
NAPOLI
Studio clinico randomizzato multicentrico di fase II con Pazopanib e Paclitaxel settimanale vs Paclitaxel settimanale nel cancro ovarico resistente o refrattario al platino - MITO-11
Istituto Nazionale Tumori - Fondazione G. Pascale
S.C. Oncologia Medica Uro-Ginecologica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
PROCLAIM-CX-2009: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors - ES
Institution: Information not provided - ES
UNITED KINGDOM
Greater London
LONDON
A Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
UNITED KINGDOM
Greater London
LONDON
ICON 6: A phase III double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance therapy, in women with ovarian cancer relapsing more than 6 months following completion of first line platinum-based treatment - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
UNITED KINGDOM
Surrey
SUTTON
A Randomised, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer - UK
The Royal Marsden Hospital
Gynaecology Unit
UNITED KINGDOM
Cambridgeshire
CAMBRIDGE
FGFR Study: Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours - UK
University of Cambridge
Department of Medicine
UNITED KINGDOM
Greater London
LONDON
Randomized, open-label, Phase 2 study of the IDO inhibitor INCB024360 versus Tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy
University College Hospital
Joint Lymphoma Clinic, 1st Floor Central
UNITED KINGDOM
Greater Manchester
ADDRESS: NOT PROVIDED - UK